best glp-1 receptor agonists Med #2: — vim Performance Medicine A clinician's perspective 📝 GLP-1

Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis

SURMOUNT-1 trial (NCT04184622, estimated study completion in May 2024) is testing the ability of tirzepatide (at doses of 5, 10, or 15 mg) to reduce weight in subjects with diabetes and obesity at 72 weeks

Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are highly effective at helping people lose weight

Competitive Landscape Which are the Leading Players in Oral Non-Peptide GLP-1 Receptor Agonist Market

Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes

Effects of the novel (Pro3)GIP antagonist and exendin(939)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin